{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Brazil Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/br/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/br/healthcare/feed.json", "description": "Latest Healthcare company headlines from Brazil, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:8dc71079705610a28482643141072be9f4ca1d8b708f06563b733048af9fa884", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "title": "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?", "content_text": "Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. BioMarin Pharmaceutical is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to ", "date_published": "2026-08-14T13:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:716db2c758fe7563d890b3fd84cd08700f39c2dc0800cb2ca92c80723134e873", "url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lantheus gains FDA nod for tau PET imaging agent in Alzheimer\u2019s", "content_text": "[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer\u2019s disease through positron emission tomography (PET). Specifically, the approval allows the use of Tauklarify in cognitively impaired adults who are investigated for Alzheimer\u2019s disease to detect if there is any tau neurofibrillary tangle pathology causing the condition. Patients should undergo diagnostic tests, such as PET scans, to determine t", "date_published": "2026-08-14T12:31:50+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "BIIB34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BIIB34", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7388c806-6af8-483e-bfe9-4089dbc8e7da/"}]}}, {"id": "source:a70cae582178023f97c17d47a0839120926b87bdd694780e1f452e8d69dbcac0", "url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mark-cuban-says-401-k-111500193.html", "title": "Mark Cuban says your 401(k) is \u2018part of the cost of health care problem.\u2019 Do you dump Big Insurance and own your values?", "content_text": "Photo by Nicola Gell / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. If your retirement savings are invested in a broad index fund, Mark Cuban says you may be helping America's largest health insurers put profits ahead of patients. \"If you own shares in a fund that owns any of the biggest insurance carriers, you are part of the cost of health care problem in this country,\" the billionaire entrepreneur wrote on X (1). Must Read Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 \u2014 6 ways to b", "date_published": "2026-08-14T11:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "H1UM34", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "H1UM34", "name": "Humana Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/613d0721-0fef-48a7-98ce-b96ef5fd3c67/"}, {"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:eff5922e101371e66c6fa7e287bc65b5cf721f7fc28b7dab3b5aa6a295c6bcc3", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "title": "Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-price", "date_published": "2026-08-14T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "B1MR34", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}, {"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:822a05382b3a8399fafba7f7840ae1b9fd0f3cab68d71bcd063a6f19e889352b", "url": "https://finance.yahoo.com/markets/stocks/articles/monolithic-power-systems-las-vegas-092800217.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/monolithic-power-systems-las-vegas-092800217.html", "title": "Monolithic Power Systems and Las Vegas Sands have been highlighted as Zacks Bull and Bear of the Day", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Zacks Equity Research shares Monolithic Power Systems MPWR as the Bull of the Day and Las Vegas Sands LVS as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Cardinal Health CAH. Here is a synopsis of all three stocks: Bull of the Day: Monolithic Power Systems Monolithic Power Systems designs, develops, and markets high-performance power solutions. The company focuses on the market for high-performance analog and mixed-signal integrated circuits (ICs). Its products are widely used in industrial applications, tele", "date_published": "2026-08-14T09:28:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:00080bf9420de03300de7c149c296f3f345081ac0dcee7187c6ee511e8f63e22", "url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "title": "Centene (CNC) Stock Still Looks Like A Bargain As Shares Jumped 145%", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how much of the recent optimism is already reflected in the price. Centene has returned 145.2% over the past year, which puts a spotlight on whether the recent share price strength is outpacing the underlying fundamentals. Raised expectations for future revenue and earnings, together with a plan to redeem part of its debt, can support the case for", "date_published": "2026-08-14T09:16:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "I1NC34", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "I1NC34", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3b0b41b8-246b-4238-9e82-a53e88ebdba4/"}, {"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:f7b5c0e0eedb244fe84ea2cfd1284610eb89b6f40eb644457ad1a82e3b552beb", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1ld0loSktMZGtkeG42ZmFfV0hrUVlJNVAyY2VSZl9fOVdmUWdnZXJPbUg0UzF3ZzVPMGlsS3VFaG9kZE0tNEpKRjdOZFFNdUxGb1E?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE1ld0loSktMZGtkeG42ZmFfV0hrUVlJNVAyY2VSZl9fOVdmUWdnZXJPbUg0UzF3ZzVPMGlsS3VFaG9kZE0tNEpKRjdOZFFNdUxGb1E?oc=5", "title": "RDOR3 - Rede D'or - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "content_text": "RDOR3 - Rede D'or - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "date_published": "2026-08-14T05:19:26+00:00", "authors": [{"name": "Investidor10"}], "tags": ["Market update", "RDOR3"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RDOR3", "name": "Rede D'Or S\u00e3o Luiz S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/5ce1e524-c6d7-4857-ab66-d7ebfbdd262a/"}]}}, {"id": "source:1c31ce144284168c245229216a4376742123f4e7e9f4fd3178ffff1dd39f025a", "url": "https://finance.yahoo.com/markets/stocks/articles/did-7up-formula-dr-pepper-051258856.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/did-7up-formula-dr-pepper-051258856.html", "title": "Did New 7UP Formula, Dr Pepper Shakes and Board Addition Just Shift Keurig Dr Pepper's (KDP) Investment Narrative?", "content_text": "Keurig Dr Pepper has recently reported second-quarter 2026 results showing sales of US$7.31 billion and net income of US$142 million, while rolling out a lime-led reformulation of 7UP and partnering with Portillo's on limited-time Dr Pepper shakes in the U.S. Alongside these product moves, the company has added Cardinal Health CFO Aaron Alt to its board as it works through a planned split into separate beverage and coffee businesses. With Aaron Alt joining the board during Keurig Dr Pepper's separation, we'll now examine how this leadership change influences its investment narrative. AI is abo", "date_published": "2026-08-14T05:12:58+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:59981c612ce15cd1484b2e39a59c6766da4145fe74d1a0ccab2a5ad215535de6", "url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "external_url": "https://finance.yahoo.com/healthcare/articles/incyte-corporation-incy-bigger-revenue-000444398.html", "title": "Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?", "content_text": "On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. HALO secures an upfront payment, milestone payments, and royalties on commercial sales, with Incyte holding an option to nominate two additi", "date_published": "2026-08-14T00:04:44+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "I1NC34", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/3b0b41b8-246b-4238-9e82-a53e88ebdba4/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV34", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/833a658d-9823-4022-a5f5-06b12953cffb/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJB34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJB34", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/62d37a00-90c8-41d9-83ff-8af28e27358a/"}]}}, {"id": "source:5a155b5cb8616cd51c5b3a9eca0282b90a1ef8317f46d88a673dfcb18e795aaa", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-stock-hits-record-221000916.html", "title": "Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy?", "content_text": "Cardinal Health CAH gave investors plenty to like in its fiscal fourth-quarter report this week, sending shares to a record high of $258 as Wall Street digests another earnings beat and an encouraging fiscal 2027 outlook. The Dividend Aristocrat's quarterly sales came in below expectations, but that was overshadowed by stronger-than-anticipated profitability, double-digit projected earnings growth, and a sizable increase to its share-repurchase authorization. With Cardinal Health also expanding several higher-growth businesses, the post-earnings setup remains compelling even after an impressiv", "date_published": "2026-08-13T22:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD34", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5587aa83-55ce-4469-b222-200a992d9332/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV34", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/833a658d-9823-4022-a5f5-06b12953cffb/"}]}}, {"id": "source:5f54df9b0bd4d9f4985c67c08d5cb6bb9181dfcdb661a1c30f70b970d3c0bfa6", "url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-goss-reports-q2-211502157.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gossamer-bio-goss-reports-q2-211502157.html", "title": "Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates", "content_text": "Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced a loss of $0.2, delivering a surprise of -17.65%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Gossamer Bio, which belongs", "date_published": "2026-08-13T21:15:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "V2EE34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "V2EE34", "name": "Veeva Systems Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/aca76fd9-3ef1-4446-a40c-7b4d01b9ffde/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRCK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRCK34", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/fd9143b6-6188-4f22-af73-02144657ad8e/"}]}}, {"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "N1VO34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "N1VO34", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/7cf82147-ee6d-4a26-b124-7dd072ebbbe1/"}]}}, {"id": "source:d5b221d008e784284f5506267720554628003b8a8b6031e7a850813ad41e63d8", "url": "https://finance.yahoo.com/healthcare/articles/sixty-compton-california-students-selected-181600514.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sixty-compton-california-students-selected-181600514.html", "title": "Sixty Compton, California Students to be Selected for Leadership and Health Advocacy Training, Powered by Health Net's $412,000 Investment", "content_text": "The company's investment in The Los Angeles Trust for Children's Health will help students build leadership skills, learn to support their peers and connect to local health care services LOS ANGELES, Aug. 11, 2026 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and company of Centene Corporation (NYSE: CNC), announced a $412,000 grant to The Los Angeles Trust for Children's Health to expand its Wellness Youth Advocate (WYA) program into Compton Unified School District. The investment will help launch the program at Compton High School, Doming", "date_published": "2026-08-13T18:16:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:f0a7380096de4910a9affacdf3f89f3158618d1b0511c0aeef0500b94f109bec", "url": "https://finance.yahoo.com/healthcare/articles/lqda-q2-earnings-top-strong-174700731.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lqda-q2-earnings-top-strong-174700731.html", "title": "LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth", "content_text": "Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 million in the year-ago quarter and beat the Zacks Consensus Estimate of $165 million. The quarterly performance was powered by continued adoption of lead drug Yutrepia. However, shares were down 10% following the second-quarter results. Shares of LQDA have surged 128.5% year to date compared with the industry's growth of 5.", "date_published": "2026-08-13T17:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:a48ab79e6d2911cf966c7ec605e452f2fa0e149f2592963120a961f03de7d20b", "url": "https://seekingalpha.com/news/4632646-s-and-p-500-tags-an-all-time-high-and-these-20-names-have-helped-fuel-the-rally?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632646-s-and-p-500-tags-an-all-time-high-and-these-20-names-have-helped-fuel-the-rally?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "S&P 500 tags an all-time high and these 20 names have helped fuel the rally", "content_text": "[S&P Market Index Concept with Financial Graphs] AlexSecret The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) climbed to a fresh all-time high of 7,816.70 on Thursday, surpassing its prior record of 7,793.68 set on August 5. The benchmark advanced 0.6% for the session and is now up 13.5% year-to-date. Broad participation has supported the advance, with 350 of the index\u2019s 500 constituents trading higher in 2026. Leadership has been highly concentrated, however, as a select group of stocks has driven much of the gains. SanDisk Corp. has stood out at the forefront, soaring 559.7% year-t", "date_published": "2026-08-13T17:40:24+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "M1RN34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "M1RN34", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e8a8abec-6856-4c97-9d97-a657c0ef4441/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "N1VO34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "N1VO34", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/7cf82147-ee6d-4a26-b124-7dd072ebbbe1/"}]}}, {"id": "source:0b0fb9490ab43a14a6f259c15ca65616328960edddf47dcbe17e6d04df9ccb3e", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "title": "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio", "content_text": "Pediatrix Medical Group, Inc. MD is a physician services provider company that offers a range of services across various specialties, including obstetrics, maternal-fetal medicine and neonatology, complemented by multiple pediatric subspecialties. The company has gained 23.9% in the year-to-date period, outperforming the industry's 1.2% growth. MD \u2014 with a market cap of $2.2 billion \u2014is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are adding further support to revenue and earnings growt", "date_published": "2026-08-13T15:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:ecd0d53289060f7914c53e120efc8e0a0a0a8e97dbd074319d2b81bfd733fdcc", "url": "https://finance.yahoo.com/healthcare/articles/carolina-complete-health-supports-young-154000860.html", "external_url": "https://finance.yahoo.com/healthcare/articles/carolina-complete-health-supports-young-154000860.html", "title": "Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp", "content_text": "Sponsorship helped 24 children from coastal North Carolina participate in educational, cultural and leadership-building activities CHARLOTTE, N.C., Aug. 13, 2026 /PRNewswire/ -- Carolina Complete Health, a subsidiary of the Centene Corporation (NYSE: CNC), sponsored the AMEXCAN Summer Camp, helping provide 24 children from coastal North Carolina with a summer experience centered on learning, leadership and personal growth.Carolina Complete Health Throughout the program, participants took part in educational workshops, cultural activities, leadership development and recreational programming des", "date_published": "2026-08-13T15:40:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "N1VO34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "N1VO34", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/7cf82147-ee6d-4a26-b124-7dd072ebbbe1/"}]}}, {"id": "source:ff25c5ba145e1a280ff65fd3c0976b6252876a953c2ac7fcd39ee7e0846a7395", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSmJWMmFiVGNNSlVWZU4wbGt2MFhCSjZfdnFTUG9yVE1WbTJoMFBwTVJya0tJN2FVNnJXeDljMG9YQ2doUnRqS0JpTE1TcF9XYl92RWRBYWxMV2ZuRGZ6MGwzWmZ1bkM1Wnc1MEVOa09xcnRwU2ozcERhNl9qZ1lWS1ZOMnA2N2l6Yk5WOHdUM18?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSmJWMmFiVGNNSlVWZU4wbGt2MFhCSjZfdnFTUG9yVE1WbTJoMFBwTVJya0tJN2FVNnJXeDljMG9YQ2doUnRqS0JpTE1TcF9XYl92RWRBYWxMV2ZuRGZ6MGwzWmZ1bkM1Wnc1MEVOa09xcnRwU2ozcERhNl9qZ1lWS1ZOMnA2N2l6Yk5WOHdUM18?oc=5", "title": "Rede D\u2019Or (RDOR3) sobe mais de 5% ap\u00f3s resultados s\u00f3lidos", "content_text": "Rede D\u2019Or (RDOR3) sobe mais de 5% ap\u00f3s resultados s\u00f3lidos", "date_published": "2026-08-13T14:59:56+00:00", "authors": [{"name": "EuQueroInvestir"}], "tags": ["Market update", "RDOR3"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RDOR3", "name": "Rede D'Or S\u00e3o Luiz S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/5ce1e524-c6d7-4857-ab66-d7ebfbdd262a/"}]}}, {"id": "source:8731f7effa586440d1d4919b715b969e8607c86f0ca67737b1e8547b3489afb6", "url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632398-unitedhealth-faces-shareholder-suit-accusing-corporate-governance-failures?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "UnitedHealth faces shareholder suit accusing corporate governance failures", "content_text": "[UnitedHealthcare headquarters in Minnetonka, Minnesota, USA] JHVEPhoto/iStock Editorial via Getty Images UnitedHealth Group (UNH [https://seekingalpha.com/symbol/UNH]) is facing an amended shareholder lawsuit that accuses the insurer of knowing about serious governance issues and doing little to ensure compliance, leading to significant losses in stock value. The suit was filed in a Minnesota federal court by the Employees\u2019 Retirement System of the State of Rhode Island and L\u00e4nsf\u00f6rs\u00e4kringar Fondf\u00f6rvaltning AB, a Swedish asset manager. Plaintiffs blame the board and senior company officers. \"O", "date_published": "2026-08-13T14:18:07+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Capital return", "UNHH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UNHH34", "name": "UnitedHealth Group Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/7b1a93f9-0786-484b-b650-7f6471178f49/"}]}}, {"id": "source:9d32db924ee34a6fd0c1a4bad9032b1acac67011e96847aee0aa81afd2b0fc08", "url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "external_url": "https://finance.yahoo.com/healthcare/articles/humana-improve-caregiver-retention-healthstream-141700367.html", "title": "Can Humana Improve Caregiver Retention With HealthStream Deal?", "content_text": "Humana Inc.'s HUM Medicaid managed care plan, Humana Healthy Horizons, is teaming up with HealthStream in Indiana to strengthen the state's home-care workforce. Under the initiative, Humana is sponsoring 1,000 Home Health Aide scholarships, helping remove financial barriers for people entering the caregiving field. The program uses HealthStream's Career Network to reach rural and underserved communities, where worker shortages can restrict access to home-based care. Humana is also deploying HealthStream's CoachUp Care platform, predictive analytics and training tools to help providers recruit ", "date_published": "2026-08-13T14:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "H1UM34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "H1UM34", "name": "Humana Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/613d0721-0fef-48a7-98ce-b96ef5fd3c67/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "R1VT34", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "R1VT34", "name": "Revvity, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c2446d3f-53b7-4da0-9819-91a42a95f1ed/"}, {"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BIIB34", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7388c806-6af8-483e-bfe9-4089dbc8e7da/"}]}}, {"id": "source:0cfcde4cddab96709ddbfbea14351e5e47db7dc607b47c80b30ee36a5f942748", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-bulls-look-optimistic-133003681.html", "title": "Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?", "content_text": "The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Medtronic (MDT). Medtronic currently has an average brokerage recommendation (ABR) of 1.90, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated", "date_published": "2026-08-13T13:30:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:c9f8b0bb43fdc75af27a72e2a94fb69b2b914b52e2eba9e72edcb333236b4303", "url": "https://finance.yahoo.com/healthcare/articles/mhs-serves-announces-recipients-over-133000474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mhs-serves-announces-recipients-over-133000474.html", "title": "MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment", "content_text": "INDIANAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Managed Health Services (MHS), a managed care entity that has been proudly serving the state of Indiana for 30 years and a Centene (NYSE: CNC) company, is proud to announce the recipients of the MHS Serves Workforce Support Program, a new statewide funding opportunity in partnership with Indiana Minority Health Coalition (IMHC) and Black Onyx Management, designed to strengthen workforce development programs that help Medicaid members prepare for employment, increase their income and build long-term economic stability.MHS The program will provide fund", "date_published": "2026-08-13T13:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "C1NC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}]}}, {"id": "source:588872d83d7698f2744870cd208a5f25049ac8d798e7bc90774e01eb646baf80", "url": "https://finance.yahoo.com/healthcare/articles/bwx-technologies-nuclear-medicine-expansion-132900353.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bwx-technologies-nuclear-medicine-expansion-132900353.html", "title": "Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?", "content_text": "BWX Technologies, Inc. BWXT is broadening its commercial nuclear portfolio through expanded capabilities in nuclear medicine and medical radioisotopes. The company's acquisition of Kinectrics in May 2025 added capabilities in the production and supply of isotopes for the radiopharmaceutical industry, enabling BWXT to expand its presence across both nuclear power and nuclear medicine markets. BWX Technologies' commercial operations segment already provides products for diagnostic imaging and radiotherapeutic treatments, including medical radioisotopes, radiopharmaceuticals and medical devices. ", "date_published": "2026-08-13T13:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:c7625b0b19766561851dad85127678768ff68611e9ab773237c6ed514a1ff9ba", "url": "https://finance.yahoo.com/markets/stocks/articles/5-undervalued-price-book-stocks-132500956.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-undervalued-price-book-stocks-132500956.html", "title": "5 Undervalued Price-to-Book Stocks Worth Buying in August", "content_text": "There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-priced stocks with great returns. The P/B ratio is calculated as below: P/B ratio = market capitalization/book value of equity This metric can help identify attractively priced stocks with upside potential. Some such stocks are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Co", "date_published": "2026-08-13T13:25:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1NC34", "B1MR34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1NC34", "name": "Centene Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a2b56ab8-95c4-45fe-9335-33da1f94e69f/"}, {"symbol": "B1MR34", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/7a440876-d01c-4de4-9256-e2c68e30a51b/"}]}}, {"id": "source:53fb05c36057c573566bfb7e8af0d607cf6f9c966d679ea9638ae9e2d7b9b533", "url": "https://finance.yahoo.com/markets/stocks/articles/nvst-buy-earnings-rebound-valuation-130400554.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/nvst-buy-earnings-rebound-valuation-130400554.html", "title": "Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median?", "content_text": "Envista Holdings Corporation NVST is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case. The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for execution setbacks even as operating momentum improves. NVST's Earnings Recovery Supports the Bull Case Adjusted earnings were 41 cents per share in the second quarter of 2026, up 57.7% year over year. Operating profit rose 73.4% to $80.3 million, while the operating margin expanded 420 basis", "date_published": "2026-08-13T13:04:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "A1LG34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "A1LG34", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/4016b2f6-afbd-4ecc-a09d-6fa829f4d63d/"}]}}, {"id": "source:53f40eb0183ab4ac381dc42e53f0c95c6e02c2bfca22e0e4a52bf13451e71d1a", "url": "https://finance.yahoo.com/markets/stocks/articles/omnicell-raises-2026-eps-outlook-125500578.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/omnicell-raises-2026-eps-outlook-125500578.html", "title": "Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins", "content_text": "Omnicell, Inc. OMCL raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund. The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive to hospital purchasing timelines. Omnicell Lifted Its 2026 Earnings Outlook Omnicell now expects adjusted earnings of $2.15-$2.30 per share for 2026, up from $1.80-$2.00 previously. Non-GAAP EBITDA guidance increased to $175-$185 million. Second-quarter adjusted earnings reached 94 c", "date_published": "2026-08-13T12:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "B1AX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "B1AX34", "name": "Baxter International Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1951509f-3248-4828-b63d-b3bf1bca14ee/"}]}}, {"id": "source:e429ec4981b80c70c477c6884ac66dfad9b345763e9d97d93c4f4c3832bb2f8c", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-add-cooper-companies-125100087.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-add-cooper-companies-125100087.html", "title": "Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now", "content_text": "The Cooper Companies, Inc.'s COO growth is fueled by CooperVision's premium lens migration and MiSight's myopia-management leadership, supported by CooperSurgical's women's health and fertility portfolio. However, channel volatility, private-label transition risks, Asia-Pacific softness and tariff/FX pressures weigh on near-term performance. Long-term opportunities remain strong, but execution and regional challenges could affect margin resilience and growth trajectory. Shares of this Zacks Rank #2 (Buy) company have lost 6.3% so far this year against the industry's 7.4% gain and the S&P 500 I", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "C1AH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "C1AH34", "name": "Cardinal Health, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/41f3d2c9-e4f2-4f5c-8d4c-4a72f1916251/"}]}}, {"id": "source:6bebd5c6d2f8662a74ba8d37058c7efaf4228f2893397c2e5001d65410bc2a61", "url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "title": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation", "content_text": "Edwards Lifesciences Corporation EW shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies. The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution. EW's 3-Month Gain Meets a Premium Valuation EW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "E1WL34", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "E1WL34", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e03db612-2d5a-4b57-b1aa-2c90a6753007/"}, {"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABTT34", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABTT34", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/54923738-62b8-4347-824e-abcfed853bbd/"}, {"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:377de25772740c4444894cc2e57c9a08c195fe57135370fa67dc64a63d10f303", "url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/fitlife-brands-inc-ftlf-beats-124002204.html", "title": "FitLife Brands Inc. (FTLF) Beats Q2 Earnings and Revenue Estimates", "content_text": "FitLife Brands Inc. (FTLF) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.17, delivering a surprise of +21.43%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. FitLife Brands , which belongs t", "date_published": "2026-08-13T12:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTC34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MDTC34", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/00f6e269-aac4-4599-899d-139667a93f62/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "S1YK34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "S1YK34", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/208e7f4d-65bf-4ddb-99d6-157334a14169/"}]}}, {"id": "source:5bfbaac008af8b9a25871bd6e53ba01f7df0e4fef16c22372fcf01342a7379ff", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-much-youd-invested-1000-123002482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/heres-much-youd-invested-1000-123002482.html", "title": "Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago", "content_text": "For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in DexCom (DXCM) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today? DexCom's Business In-Depth With that in mind, let's take a look", "date_published": "2026-08-13T12:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "D1EX34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "D1EX34", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b2c00c38-8c26-4d9c-a6aa-ac60da580f5e/"}]}}, {"id": "source:356b9804c9a950cf8dc50d3ef8ffae3b5a2bb261fcdebe7b7d66a4ec0cf11c6d", "url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "title": "Zoetis (ZTS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on a reported basis and a 1% decline on an organic operational basis driven by a 1% decrease in volume.Adjusted Net Income -- $781 million, declining 2% on an organic operational basis.Adjusted Diluted EPS -- $1.87, representing 4% growth year over year and benefiting from a lower share count.U.S. Segment Revenue ", "date_published": "2026-08-13T12:01:05+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:6a718becf991eeeaf34cd79c446bedd27ee9e3434e04d0e0d2465e2556e48a95", "url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "external_url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "title": "This Healthcare Services Stock Has 37% Upside", "content_text": "Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July\u2019s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%. Continue Reading", "date_published": "2026-08-13T12:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "I1QV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "I1QV34", "name": "IQVIA Holdings Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ee64193e-140b-44a5-9ea1-b90b0c4cdc9e/"}]}}, {"id": "source:f4f0cfb1be75e5806057ed93225c6bd944ad0434bab79d80d251ca250823f59c", "url": "https://finance.yahoo.com/healthcare/articles/bio-techne-corrects-dividend-announcement-103000470.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bio-techne-corrects-dividend-announcement-103000470.html", "title": "Bio-Techne Corrects Dividend Announcement", "content_text": "MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged. Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common ", "date_published": "2026-08-13T10:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "T1CH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1CH34", "name": "Bio-Techne Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/86977c03-7776-48b0-be7e-931154374cb2/"}]}}, {"id": "source:1fb430f4d1b71b75f67c6b22999fe9bcfcc63d54812fb79c7524b788dcf10acc", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "content_text": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "date_published": "2026-08-13T10:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LILY34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LILY34", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/8803d47b-8799-4595-a90b-e8cca2f22b2d/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GILD34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD34", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/5587aa83-55ce-4469-b222-200a992d9332/"}]}}]}